Opaganib

An overview of the investigational drug Opaganib

Opaganib
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Opaganib is an investigational drug that is being studied for its potential therapeutic effects in various medical conditions, including cancer and viral infections. It is a small molecule inhibitor that targets specific pathways involved in disease progression.

Mechanism of Action

Opaganib is known to inhibit the activity of sphingosine kinase-2 (SK2), an enzyme that plays a crucial role in the sphingolipid metabolic pathway. By inhibiting SK2, Opaganib reduces the production of sphingosine-1-phosphate (S1P), a lipid signaling molecule that is involved in cell proliferation, survival, and inflammation. This mechanism is thought to contribute to its potential anti-cancer and anti-inflammatory effects.

Therapeutic Applications

Cancer

Opaganib is being investigated for its use in treating various types of cancer, including prostate cancer, breast cancer, and glioblastoma. Its ability to inhibit SK2 and reduce S1P levels may help to slow down tumor growth and enhance the effectiveness of other cancer therapies.

Viral Infections

Research is also being conducted on the use of Opaganib in treating viral infections, such as COVID-19. The drug's anti-inflammatory properties and its ability to modulate immune responses make it a candidate for reducing the severity of viral infections.

Clinical Trials

Opaganib is currently undergoing clinical trials to evaluate its safety and efficacy in humans. These trials are essential for determining the appropriate dosing, potential side effects, and overall therapeutic value of the drug.

Side Effects

As with any investigational drug, Opaganib may have side effects. Commonly reported side effects in clinical trials include gastrointestinal disturbances, fatigue, and headache. The safety profile of Opaganib continues to be evaluated in ongoing studies.

Development and Research

Opaganib is being developed by RedHill Biopharma, a biopharmaceutical company focused on the development of novel therapeutics. The drug's development is part of a broader effort to explore new treatments for diseases with unmet medical needs.

Related pages

• Sphingosine kinase
• Sphingolipid metabolism
• Cancer treatment
• Antiviral drugs

• 

  Opaganib